Andrew J. Armstrong, MD, MSc

Related Content

Services

• Prostate Cancer

Department / Division:
Medicine / Medical Oncology

Address:
DUMC 3850
Durham, NC 27710

Appointment Telephone:
919-668-8108

Office Telephone:
919-668-8797

Fax Telephone:
919-668-7117

• MD, University of Virginia School of Medicine, 2000

• Internal Medicine, Hospital of the University of Pennsylvania, 2000-2003

• Medical Oncology, Johns Hopkins University (Maryland), 2003-2006

• MSc, Clinical Investigation, Johns Hopkins School of Public Health (Maryland), 2007

Clinical Interests:
Drug development and novel strategies for the treatment and management of advanced prostate cancer and other GU malignancies, targeted therapy, mTOR/Akt pathway inhibitor; prognostic and surrogate models in GU malignancies, perioperative biologic therapeutics

Research Interests:
1. Predictors of sensitivity and clinical efficacy of mTOR inhibitors in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in GU malignancies
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, and bladder cancer
5. Design of rational combination therapies with mTOR inhibition in metastatic hormone-refractory prostate cancer
6. Exploration of resistance mechanisms to rapamycin and its analogues in prostate cancer
7. Developing prognostic models for progression and survival in metastatic hormone-refractory prostate cancer
8. Examining surrogate markers of mortality in metastatic hormone-refractory prostate cancer
9.      Non-clear cell renal cell carcinoma:  natural history, sensitivity to novel agents including mTOR and VEGF inhibition

Representative Publications:
Srinivasan R, Armstrong AJ, Dahut W, George DJ. Anti-angiogenic therapy in renal cell cancer. BJU Int. 2007 May;99(5 Pt B):1296-300. (2007) Abstract

Mendiratta P, Armstrong AJ, George DJ. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol. 2007;9 Suppl 1:S9-S19. (2007) Abstract

Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Clin Cancer Res. 2007 Nov 1;13(21):6396-403. (2007) Abstract

Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 1;25(25):3965-70. (2007) Abstract

Armstrong AJ, Febbo PG, George DJ, Moul J. Systemic strategies for prostate cancer. Minerva Urol Nefrol. 2007 Mar;59(1):11-25. (2007) Abstract

Armstrong AJ, Eisenberger M. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture? Nat Clin Pract Urol. 2006 May;3(5):246-7. (2006) Abstract

Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol. 2006 May;16(3):138-45. (2006) Abstract

Armstrong AJ, Carducci MA. Novel therapeutic approaches to advanced prostate cancer. Clin Adv Hematol Oncol. 2005 Apr;3(4):271-82. (2005) Abstract

Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep. 2005 May;7(3):220-7. (2005) Abstract

Armstrong AJ, Carducci MA. Advanced prostate cancer: the future. Can J Urol. 2005 Jun;12 Suppl 2:42-7. (2005) Abstract

Nightingale RW, Camacho DL, Armstrong AJ, Robinette JJ, Myers BS. Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine. J Biomech. 2000 Feb;33(2):191-7. (2000) Abstract

Fukasawa K, Zhou R, Matten WT, Armstrong AJ, Daar I, Oskarsson M, Sathyanarayana BK, Maclvor L, Wood TG, Vande Woude GF. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Oncogene. 1995 Oct 19;11(8):1447-57. (1995) Abstract